A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session1ijbcqig5h967g9a5u9oj2qh0i0o7m50): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 197

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3145
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

[Clinical development of OCT]. | LitMetric

[Clinical development of OCT].

Clin Calcium

Clinical Affairs Dept. Chugai Phamaceutical Co., LTD.

Published: June 2002

OCT was first synthesized in the late 1980s, and clinical development was started in July 1991 with entry into Phase I. By the time the application for manufacturing approval was submitted, in February 1998, 15 clinical studies had been carried out, including 2 double-blind comparative studies and 5 long-term administration studies. The efficacy and safety of OCT were evaluated on the basis of clinical data obtained from totally 977 participants. OCT was found to be effective against secondary hyperparathyroidism in long-term dialysis patients, as it markedly decreased the PTH level, and showed ameliorative effects in bone tissue showing high bone turnover, and on bone metabolic markers. Adding to above clinical effects, because safety data demonstrated that there was no significant drawback except for an increase of serum calcium level, manufacturing approval was finally achieved in July 2000, under the commercial name "Oxarol injection".

Download full-text PDF

Source

Publication Analysis

Top Keywords

manufacturing approval
8
[clinical development
4
development oct]
4
oct] oct
4
oct synthesized
4
synthesized late
4
late 1980s
4
clinical
4
1980s clinical
4
clinical development
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!